Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07325136 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
A Phase 1 study of Relapsed/Refractory Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 11
- Study locations
NCT07325136 is a Phase 1 study of Relapsed/Refractory Small Cell Lung Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 240 participants. The trial reports 11 study locations across 10 states.
The verdict
NCT07325136, a Phase 1 study of Relapsed/Refractory Small Cell Lung Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Nivolumab in participants with Relapsed/Refractory Small Cell Lung Cancer
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG BMS-986525
Study Locations (11)
Other
- Local Institution - 0003 - Craiova
- Local Institution - 0009 - Madrid
Michigan
- Local Institution - 0011 - Detroit
New York
- Local Institution - 0026 - Buffalo
North Carolina
- Local Institution - 0005 - Durham
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Tennessee
- SCRI Oncology Partners - Nashville
Milano
- Local Institution - 0001 - Rozzano
Osaka
- Local Institution - 0020 - Hirakata
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2026-02-03 |
| Est. Completion | 2029-04-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07325136
The ClinicalTrials.gov registry entry for NCT07325136 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT07325136 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Other, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT07325136 about?
NCT07325136 is a clinical study titled "A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer". The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Nivolumab in participants with Relapsed/Refractory Small Cell Lung Cancer
What is the current status of trial NCT07325136?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2026-02-03. Estimated completion is 2029-04-24.
What conditions does trial NCT07325136 study?
This clinical trial studies the following conditions: Relapsed/Refractory Small Cell Lung Cancer.
What interventions are being tested in trial NCT07325136?
The interventions under investigation include: Nivolumab (DRUG), BMS-986525 (DRUG).
Who is sponsoring clinical trial NCT07325136?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07325136 being conducted?
This trial has 11 study locations across Michigan, New York, North Carolina, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.